| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 6, 2025 | UTHR United Therapeutics Corp | Rothblatt Martine A | Chairperson &CEO | Sell | 8,000 | $447.95 | $3,583,612.06 | -49.9% | +8.0% | - | |
| Oct 3, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 192,404 | $837.93 | $161,220,401.35 | - | +28.6% | - | |
| Oct 3, 2025 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 11,595 | $57.72 | $669,232.09 | -14.2% | -36.4% | - | |
| Oct 2, 2025 | SUPN Supernus Pharmaceuticals, Inc. | Khattar Jack A.64 | President, CEO | Sell | 1,904 | $48.06 | $91,506.24 | -0.2% | +3.6% | - | |
| Oct 2, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 112,596 | $821.55 | $92,503,361.30 | - | +31.1% | - | |
| Oct 2, 2025 | UTHR United Therapeutics Corp | Mahon Paul A | EVP &General Counsel | Sell | 11,000 | $436.60 | $4,802,573.67 | -3.7% | +9.9% | - | |
| Oct 2, 2025 | ELTP Elite Pharmaceuticals Inc /nv/ | Plassche Douglas | EVP Operations | Sell | 800,000 | $0.62 | $499,200.00 | -18.6% | - | - | |
| Oct 2, 2025 | UTHR United Therapeutics Corp | Rothblatt Martine A | Chairperson &CEO | Sell | 8,000 | $430.17 | $3,441,321.52 | -55.5% | +9.9% | - | |
| Oct 1, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 135,193 | $794.15 | $107,363,016.18 | - | +30.8% | - | |
| Oct 1, 2025 | RMTI Rockwell Medical, Inc. | Neri Jesse61 | SVP And CFO | Sell | 886 | $1.19 | $1,054.34 | -0.7% | -31.5% | - | |
| Oct 1, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 215,822 | $821.47 | $177,290,448.45 | - | +30.8% | - | |
| Oct 1, 2025 | RMTI Rockwell Medical, Inc. | Strobeck Mark72 | President And CEO | Sell | 6,926 | $1.19 | $8,241.94 | -2.1% | -31.5% | - | |
| Oct 1, 2025 | RMTI Rockwell Medical, Inc. | Chole Timothy73 | SVP And CCO | Sell | 2,868 | $1.19 | $3,412.92 | -2.2% | -31.5% | - | |
| Oct 1, 2025 | SUPN Supernus Pharmaceuticals, Inc. | Khattar Jack A.64 | President, CEO | Sell | 40,173 | $48.07 | $1,931,116.11 | -3.3% | +3.9% | - | |
| Oct 1, 2025 | RMTI Rockwell Medical, Inc. | Hunter Heather | SVP, Chief Operating Officer | Sell | 2,868 | $1.19 | $3,412.92 | -2.1% | -31.5% | - | |
| Oct 1, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $27.20 | $13,602.40 | -0.7% | +0.0% | - | |
| Oct 1, 2025 | HIMS Hims & Hers Health, Inc. | Chi Michael | Chief Commercial Officer | Sell | 250 | $56.00 | $14,000.00 | - | -41.3% | - | |
| Sep 30, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Bedrosian Camille L64 | Chief Medical Officer | Sell | 12,039 | $14.58 | $175,517.78 | -6.2% | -10.3% | - | |
| Sep 30, 2025 | PAHC Phibro Animal Health Corp | Bendheim Jack49 | President And CEO | Sell | 20,664 | $40.38 | $834,412.32 | -33.7% | -6.7% | - | |
| Sep 30, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Frates James M83 | Chief Financial Officer | Sell | 10,558 | $14.65 | $154,650.42 | -3.6% | -10.3% | - | |
| Sep 30, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 113,694 | $763.39 | $86,793,273.90 | - | +41.4% | - | |
| Sep 30, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Klee Justin B.60 | Co-chief Executive Officer | Sell | 29,975 | $14.38 | $430,952.12 | -0.4% | -10.3% | - | |
| Sep 30, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Cohen Joshua B60 | Co-chief Executive Officer | Sell | 29,933 | $14.35 | $429,468.84 | -0.4% | -10.3% | - | |
| Sep 30, 2025 | SUPN Supernus Pharmaceuticals, Inc. | Khattar Jack A.64 | President, CEO | Sell | 8,588 | $48.25 | $414,371.00 | -0.7% | +7.2% | - | |
| Sep 30, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Mazzariello Gina53 | Chief Legal Officer | Sell | 8,828 | $14.58 | $128,668.98 | -5.6% | -10.3% | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.